ResearcherJohns Hopkins UniversityNo recent work listed
Qichun Wei
Matched on ORCID iD 0000-0002-8688-5000; OpenAlex author ID A5017140872. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 5
- Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… Co-author DOI 10.1186/s12885-022-09974-7↗
- Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Co-author DOI 10.1634/theoncologist.2018-0696↗
- Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. Last author DOI 10.1186/s13014-016-0714-7↗
- [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Advances of stereotactic body radiotherapy in pancreatic cancer. Co-author DOI 10.3978/j.issn.1000-9604.2015.04.12↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tingbo Liang · 4 shared papers, 2016–2022 · strength 0.32
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7↗
- Paper Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cance… DOI 10.1634/theoncologist.2018-0696↗
- Paper Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial locat… DOI 10.1186/s13014-016-0714-7↗
- Risheng Que · 3 shared papers, 2016–2022 · strength 0.27
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7↗
- Paper Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cance… DOI 10.1634/theoncologist.2018-0696↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Xueli Bai · 3 shared papers, 2016–2019 · strength 0.18
- Paper Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cance… DOI 10.1634/theoncologist.2018-0696↗
- Paper Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial locat… DOI 10.1186/s13014-016-0714-7↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Ri‐Sheng Yu · 3 shared papers, 2016–2019 · strength 0.18
- Paper Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cance… DOI 10.1634/theoncologist.2018-0696↗
- Paper Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial locat… DOI 10.1186/s13014-016-0714-7↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Bingfeng Huang · 1 shared paper, 2022 · strength 0.14
- Tao Ma · 1 shared paper, 2022 · strength 0.14
- Mengyi Lao · 1 shared paper, 2022 · strength 0.14
- Wei Chen · 1 shared paper, 2022 · strength 0.14
- Xueli Bai · 1 shared paper, 2022 · strength 0.14
- Jianying Lou · 2 shared papers, 2016–2019 · strength 0.13
- Paper Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cance… DOI 10.1634/theoncologist.2018-0696↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Ying Yuan · 1 shared paper, 2019 · strength 0.08
- Xiang Li · 1 shared paper, 2019 · strength 0.08
- Qi Zhang · 1 shared paper, 2019 · strength 0.08
- Yiwen Chen · 1 shared paper, 2019 · strength 0.08
- Pintong Huang · 1 shared paper, 2019 · strength 0.08
- Yinan Shen · 1 shared paper, 2019 · strength 0.08
- Lauren M. Rosati · 1 shared paper, 2015 · strength 0.07
- Joseph M. Herman · 1 shared paper, 2015 · strength 0.07
- Guogang Li · 1 shared paper, 2016 · strength 0.05
- Wei Yu · 1 shared paper, 2016 · strength 0.05
- Lei Zheng · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.